Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that the humanized anti-soluble aggregated amyloid-beta (A?) monoclonal antibody "LEQEMBI®" has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback